Literature DB >> 26868336

The promise and challenges of rare cancer research.

Kimberly M Komatsubara1, Richard D Carvajal2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26868336     DOI： 10.1016/S1470-2045(15)00485-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  8 in total

Review 1.  A framework for fibrolamellar carcinoma research and clinical trials.

Authors:  Timothy A Dinh; Alan F Utria; Kevin C Barry; Rosanna Ma; Ghassan K Abou-Alfa; John D Gordan; Elizabeth M Jaffee; John D Scott; Jessica Zucman-Rossi; Allison F O'Neill; Mark E Furth; Praveen Sethupathy
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-02-21       Impact factor: 73.082

2.  Characteristics of Early Phase Clinical Trials for Rare Cancers: Insights From Interviews With Stakeholders.

Authors:  M Dooms; R Saesen; I Steemans; J Lansens; I Huys
Journal:  Front Pharmacol       Date:  2022-05-02       Impact factor: 5.988

3.  Travel burden associated with rare cancers: The example of Merkel cell carcinoma.

Authors:  Rahul Jain; Joseph Menzin; Kristina Lachance; Patrick McBee; Hemant Phatak; Paul T Nghiem
Journal:  Cancer Med       Date:  2019-04-05       Impact factor: 4.452

4.  Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers.

Authors:  Rivka R Colen; Christian Rolfo; Murat Ak; Mira Ayoub; Sara Ahmed; Nabil Elshafeey; Priyadarshini Mamindla; Pascal O Zinn; Chaan Ng; Raghu Vikram; Spyridon Bakas; Christine B Peterson; Jordi Rodon Ahnert; Vivek Subbiah; Daniel D Karp; Bettzy Stephen; Joud Hajjar; Aung Naing
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

5.  Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review.

Authors:  Fausto Petrelli; Francesca Consoli; Antonio Ghidini; Gianluca Perego; Andrea Luciani; Paola Mercurio; Alfredo Berruti; Salvatore Grisanti
Journal:  Front Immunol       Date:  2021-09-20       Impact factor: 7.561

6.  Differences in health care experiences between rare cancer and common cancer patients: results from a national cross-sectional survey.

Authors:  Eline de Heus; Vivian Engelen; Irene Dingemans; Carol Richel; Marga Schrieks; Jan Maarten van der Zwan; Marc G Besselink; Mark I van Berge Henegouwen; Carla M L van Herpen; Saskia F A Duijts
Journal:  Orphanet J Rare Dis       Date:  2021-06-01       Impact factor: 4.123

7.  Phase 2 study of pembrolizumab in patients with advanced rare cancers.

Authors:  Aung Naing; Funda Meric-Bernstam; Bettzy Stephen; Daniel D Karp; Joud Hajjar; Jordi Rodon Ahnert; Sarina A Piha-Paul; Rivka R Colen; Camilo Jimenez; Kanwal P Raghav; Renata Ferrarotto; Shi-Ming Tu; Matthew Campbell; Linghua Wang; Sarjeel H Sabir; Coya Tapia; Chantale Bernatchez; Michael Frumovitz; Nizar Tannir; Vinod Ravi; Saria Khan; Jeane M Painter; Abulrahman Abonofal; Jing Gong; Anas Alshawa; Lacey M McQuinn; Mingxuan Xu; Sara Ahmed; Vivek Subbiah; David S Hong; Shubham Pant; Timothy A Yap; Apostolia M Tsimberidou; Ecaterina E Ileana Dumbrava; Filip Janku; Siqing Fu; Richard M Simon; Kenneth R Hess; Gauri R Varadhachary; Mouhammed Amir Habra
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751

8.  Editorial: New Insights Into the Landscape of Rare Tumors: Translational and Clinical Research Perspective.

Authors:  Alessandro De Vita; Alberto Bongiovanni; Jean-Yves Blay; Toni Ibrahim
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.